Bispecific Or Bifunctional, Or Multispecific Or Multifunctional, Antibody Or Fragment Thereof Patents (Class 424/136.1)
  • CANCER STEM CELL ISOLATION
    Publication number: 20140314675
    Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.
    Type: Application
    Filed: September 7, 2012
    Publication date: October 23, 2014
    Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
  • Modulation of Midbody Derivatives
    Publication number: 20140314836
    Abstract: The number of midbody derivatives in a cell may be modulated by modulating autophagy induced by NBR1. Exemplary methods include modulating the amount or activity of NBR1 in the cell, potentiating or inhibiting binding between NBR1 and Cep55 in the cell, or modulating the amount of Cep55 in the cell. These methods can be used in the treatment of cancers or in methods of reprogramming cells.
    Type: Application
    Filed: September 7, 2012
    Publication date: October 23, 2014
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Stephen J. Doxsey, Tse-Chun Kuo, Chun-Ting Chen
  • BI-SPECIFIC ANTIBODIES FOR MEDICAL USE
    Publication number: 20140314764
    Abstract: A bispecific antibody format devoid of an active Fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on B-cells, for use in the treatment or prevention of B cell mediated autoimmune diseases.
    Type: Application
    Filed: November 19, 2012
    Publication date: October 23, 2014
    Inventors: Gundram Jung, Ludger Grosse-Hovest
  • Fusion polypeptides capable of activating receptors
    Patent number: 8865430
    Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: October 21, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
  • HETERODIMERIC BISPECIFIC ANTIBODIES
    Publication number: 20140308285
    Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 16, 2014
    Applicant: Amgen Inc.
    Inventors: Wei YAN, Martin J. PENTONY, Luis G. BORGES, Mark L. MICHAELS
  • PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PANCREATIC CANCER
    Publication number: 20140308283
    Abstract: This invention relates to a pharmaceutical composition for treatment and/or prevention of pancreatic cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 to 12 or more consecutive amino acid residues.
    Type: Application
    Filed: August 3, 2012
    Publication date: October 16, 2014
    Applicant: TORAY INDUSTRIES, INC.
    Inventors: Yoshitaka Minamida, Fumiyoshi Okano, Takanori Saito
  • DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20140308286
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: March 19, 2014
    Publication date: October 16, 2014
    Applicant: AbbVie Inc.
    Inventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu
  • VEGF/DLL4 binding agents and uses thereof
    Patent number: 8858941
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: October 14, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • ALBUMIN BINDING ANTIBODIES AND BINDING FRAGMENTS THEREOF
    Publication number: 20140302033
    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 9, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Pavalli Bhatta, Sam Phillip Heywood, David Paul Humphreys
  • MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF
    Publication number: 20140302038
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.
    Type: Application
    Filed: November 6, 2012
    Publication date: October 9, 2014
    Inventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao
  • ANTI-C-MET/ANTI-EGFR BISPECIFIC ANTIBODIES
    Publication number: 20140302029
    Abstract: There are provided an anti-c-Met/anti-EGFR bispecific antibody, a method for preventing and/or treating cancer using the same, and an anti-EGFR scFv fragment.
    Type: Application
    Filed: March 31, 2014
    Publication date: October 9, 2014
    Inventors: MI YOUNG CHO, SEUNG HYUN LEE, KWANG HO CHEONG, POWEI LIN, JAE WOONG HWANG, CHRISTINA YI, YOUNG JUN KOH
  • ANTI-C-MET Tandem Fc Bispecific Antibodies
    Publication number: 20140302035
    Abstract: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.
    Type: Application
    Filed: March 6, 2014
    Publication date: October 9, 2014
    Applicants: ADIMAB, LLC, MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Brian HARMS, Neeraj KOHLI, Alexey LUGOVSKOY, Melissa GEDDIE, Eric Mark KRAULAND, WIlliam George ROACH, Stephen SU, Adnan ABU-YOUSIF
  • PROTEINS SPECIFIC FOR BAFF AND B7RP1
    Publication number: 20140302036
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Application
    Filed: March 10, 2014
    Publication date: October 9, 2014
    Applicant: Amgen Inc.
    Inventors: Hailing HSU, Ming ZHANG, Gunasekaran KANNAN, Frederick W. JACOBSEN, Wayne TSUJI
  • BISPECIFIC-Fc MOLECULES
    Publication number: 20140302037
    Abstract: Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 9, 2014
    Applicant: Amgen Inc.
    Inventors: Luis G. BORGES, Patrick A. BAEUERLE, Wei YAN, Mark L. MICHAELS
  • NOVEL MODULATORS AND METHODS OF USE
    Publication number: 20140302034
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
    Type: Application
    Filed: December 7, 2011
    Publication date: October 9, 2014
    Applicant: Stem CentRx, Inc.
    Inventors: Alex Bankovich, Orit Foord, Johannes Hampl, Scott J. Dylla
  • Dual variable domain immunnoglobulins and uses thereof
    Patent number: 8853365
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: October 7, 2014
    Assignee: ABBVIE Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20140294833
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Application
    Filed: January 14, 2014
    Publication date: October 2, 2014
    Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
  • MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI)
    Publication number: 20140294832
    Abstract: Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 2, 2014
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Zhuozhi Wang, John Murphy, Tobias Marquardt, Dieter Moosmayer
  • TARGETING REGULATORY T CELLS WITH HETERODIMERIC PROTEINS
    Publication number: 20140294759
    Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
    Type: Application
    Filed: March 17, 2014
    Publication date: October 2, 2014
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi, John Desjarlais
  • TARGETING REGULATORY T CELLS WITH HETERODIMERIC PROTEINS
    Publication number: 20140294836
    Abstract: The present invention provides methods and compositions comprising a heterodimeric antibody comprising a first monomer comprising a first variant heavy chain constant region and an anti-CD4 binding moiety. The heterodimeric antibody also comprises a second monomer comprising: a second variant heavy chain constant region and an anti-CD25 binding moiety. In some cases, the pIs of the first and second variant heavy chain constant regions are at least 0.5 logs apart.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Applicant: Xencor, Inc.
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi
  • ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS
    Publication number: 20140294829
    Abstract: The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including pain, asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient.
    Type: Application
    Filed: March 24, 2014
    Publication date: October 2, 2014
    Applicant: GENENTECH, INC.
    Inventor: David L. Shelton
  • BISPECIFIC ANTI-CMET/ANTI-HER2 ANTIBODIES
    Publication number: 20140294838
    Abstract: There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 2, 2014
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Mi Young CHO, Powei Lin, Seung Hyun Lee, Kwang Ho Cheong, Young Jun Koh, Christina Yi, Jae Woong Hwang
  • Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure
    Publication number: 20140294826
    Abstract: Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes at least one or a plurality of disease agents that are toxins, for example at least one of a ricin toxin, a Shiga toxin, or an anthrax toxin.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 2, 2014
    Applicant: Tufts University
    Inventor: Charles B. Shoemaker
  • LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER
    Publication number: 20140294765
    Abstract: This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LSR molecules, which are suitable drugs for immunotherapy and treatment of specific cancer.
    Type: Application
    Filed: June 19, 2013
    Publication date: October 2, 2014
    Applicant: COMPUGEN LTD.
    Inventors: Gad S. Cojocaru, Liat Dassa, Galit Rotman, Ofer Levi, Andrew Pow, Shirley Sameach-Greenwald, Zurit Levine
  • Methylated Peptides Derived from Tau Protein and Their Antibodies for Diagnosis and Therapy of Alzheimer's Disease
    Publication number: 20140294839
    Abstract: In sporadic Alzheimer's disease, neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. Immunoassays have been developed recently that detect tau in biological specimens, thus providing a means for pre-mortem diagnosis of Alzheimer's disease, which has remained elusive. These assays have been improved by the analysis of relevant post-translational modifications, such as phosphorylation, however opportunity for improvement remains. The present invention addresses this issue by disclosing synthetic methylated peptides derived from the tau protein of paired helical filaments and non-diseased control brain. Alzheimer's disease specificity is provided by the presence or absence of methyl moieties on lysine residues and differences between mono-, di-, and tri-methylation.
    Type: Application
    Filed: October 22, 2012
    Publication date: October 2, 2014
    Inventors: Jeffrey A. Kuret, Kristen E. Funk, Jyanyu Austin Yang, Stefani Thomas
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20140294835
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 2, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • METHOD OF COMBINATION THERAPY USING AN EGFR ANTAGONIST AND ANTI-C-MET ANTIBODY
    Publication number: 20140294830
    Abstract: A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Applicants: SAMSUNG LIFE WELFARE FOUNDATION, SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Saet Byoul LEE, Jae Hyun Choi, Kyung Ah Kim, Ji Min Lee, Yun Ju Jeong
  • FUSION PROTEIN COMPRISING ANTI-C-MET ANTIBODY AND VEGF-BINDING FRAGMENT
    Publication number: 20140294837
    Abstract: There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 2, 2014
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Yun Jeong SONG, Ho Yeong SONG, Seung Hyun LEE, Kyung Ah KIM, Yun Ju JEONG
  • ANTIBODIES THAT BIND TO OX40 AND THEIR USES
    Publication number: 20140294824
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 2, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Antoine ATTINGER, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • LIGHT CHAIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20140294758
    Abstract: Provided are recombinant antibodies comprising one or more peptides fused to the C-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the C-terminus of the light chain constant region are described and shown to be surprisingly active.
    Type: Application
    Filed: June 24, 2012
    Publication date: October 2, 2014
    Inventor: Stephen D. Gillies
  • TANDEM FC BISPECIFIC ANTIBODIES
    Publication number: 20140294834
    Abstract: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 2, 2014
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Brian HARMS, Neeraj KOHLI, Alexey LUGOVSKOY, Stephen SU, Melissa GEDDIE
  • Anti-LRP6 antibodies
    Patent number: 8846041
    Abstract: The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: September 30, 2014
    Assignee: Genentech, Inc.
    Inventors: Eric Bourhis, Tim Cao, Rick Carano, Andrea Cochran, Mike Costa, Venita DeAlmeida, James Ernst, Yan Gong, Rami Hannoush, Paul Polakis, Bonnee Rubinfeld, Mark Solloway, Yan Wu
  • Multi-specific FAB fusion proteins and methods of use
    Patent number: 8846042
    Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: September 30, 2014
    Assignee: Fabion Pharmaceuticals, Inc.
    Inventor: Hongxing Zhou
  • VACCINE PREPARATION CONTAINING TRIFUNCTIONAL ANTIBODIES WITH ANTIGEN IMMUNOGENICITY ENHANCER PROPERTIES
    Publication number: 20140286999
    Abstract: The present invention refers to a pharmaceutical composition containing trifunctional bispecific and/or trispecific antibodies being capable of binding to a specific target antigen(s) for use in a method of immunizing mammals against diseases in which said target antigen(s) is (are) involved, and further to a pharmaceutical composition containing trifunctional bispecific and/or trispecific antibodies being capable of binding to (a) specific target antigen (s) which is (are) involved in a disease of a mammal, specifically a human.
    Type: Application
    Filed: May 16, 2012
    Publication date: September 25, 2014
    Applicant: TRION Research Gmbh
    Inventor: Horst Lindhofer
  • MET-BINDING AGENTS AND USES THEREOF
    Publication number: 20140286951
    Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Inventors: Austin L. GURNEY, Ming-Hong Xie, Christopher John Bond
  • Dosage regimen for administering a CD19XCD3 bispecific antibody
    Patent number: 8840888
    Abstract: Provided herein is a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19.times.CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: September 23, 2014
    Assignee: Micromet AG
    Inventors: Dirk Nagorsen, Peter Kufer, Gerhard Zugmaier, Patrick Baeuerle
  • DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17
    Publication number: 20140271458
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: AbbVie Inc.
    Inventors: Tariq Ghayur, JiJie Gu, Maria Harris, Carrie Goodreau, Sonal Saluja
  • Interferon Alpha and Omega Antibody Antagonists
    Publication number: 20140271648
    Abstract: Broadly neutralizing interferon-? and interferon-? antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFN? and IFN?.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Pan-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20140271647
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Applicant: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • Dual Specific Binding Proteins Directed Against TNF
    Publication number: 20140271457
    Abstract: Engineered multivalent and multispecific binding proteins that bind TNF? and IL-13, TNF? and PGE2, or TNF? and NGF are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: ABBVIE INC.
    Inventors: Tariq Ghayur, Carrie Goodreau
  • METHODS AND COMPOSITIONS FOR INHIBITING STAPHYLOCOCCUS AGGLUTINATION IN BLOOD
    Publication number: 20140271649
    Abstract: Certain embodiments are directed to methods of inhibiting Staphylococcal infection comprising administering effective amounts of a ClfA inhibitor and a thrombin inhibitor to a patient.
    Type: Application
    Filed: July 13, 2012
    Publication date: September 18, 2014
    Applicant: The University of Chicago
    Inventors: Olaf Schneewind, Dominique Missiakas, Molly Mcadow, Hwan Keun Kim
  • MONOSPECIFIC AND BISPECIFIC HUMAN MONOCLONAL ANTIBODIES TARGETING INSULIN-LIKE GROWTH FACTOR II (IGF-II)
    Publication number: 20140271646
    Abstract: Monoclonal antibodies (mAbs), antigen binding fragments and engineered antibody domains (eAds) that specifically bind IGF-II are disclosed herein. In some embodiments, these mAbs and eAds are included in a bispecific mAb. In some embodiments, the bispecific antibody specifically binds two different epitopes of IGF-II. Methods of using these mAbs, antigen binding fragments, and eAds, bispecific antibodies, and nucleic acids encoding these mAbs, antigen binding fragments, and eAds, bispecific antibodies are also disclosed.
    Type: Application
    Filed: October 16, 2012
    Publication date: September 18, 2014
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Yang Feng
  • Notch1 binding agents and methods of use thereof
    Patent number: 8834875
    Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: September 16, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventor: Edward Thein Htun Van Der Horst
  • Bispecific Molecules That Are Immunoreactive with Immune Effector Cells of a Companion Animal That Express an Activating Receptor and Cells That Express B7-H3 and Uses Thereof
    Publication number: 20140255407
    Abstract: The present invention relates to bispecific molecules that are immunoreactive to an activating receptor of a companion animal immune effector cell and to B7-H3, and to the use of such bispecific molecules in the treatment of cancer in companion animals.
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: MacroGenics, Inc.
    Inventor: Scott Koenig
  • Removal of Monomeric Targets
    Publication number: 20140255405
    Abstract: The present invention relates to a novel method for the removal of monomeric targets from bodily fluids, and to pharmaceutical compositions for use in such methods.
    Type: Application
    Filed: May 29, 2012
    Publication date: September 11, 2014
    Inventors: Roland Beckmann, Kristian Jensen
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20140255408
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: May 21, 2014
    Publication date: September 11, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES
    Publication number: 20140255406
    Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: Eli Lilly and Company
    Inventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
  • Cytomegalovirus surface protein complex for use in vaccines and as a drug target
    Patent number: 8828399
    Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: September 9, 2014
    Assignee: The Trustees of Princeton University
    Inventors: Thomas Shenk, Dai Wang
  • Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
    Patent number: 8822645
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: September 2, 2014
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Jijie Gu, Peter C. Isakson
  • KLK-13 antibody inhibitor for treating dry eye
    Patent number: 8821874
    Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: September 2, 2014
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao